Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.
HCT provides a significant survival benefit for patients with MDS aged 50 to 75 OLD RETIRED PAGE
Nakamura, R et al., ASH oral abstract presentation, December 2020—Patients ages 65 and older with MDS who received an allogeneic hematopoietic cell transplantation (alloHCT) saw a similar benefit to overall survival (OS) as younger patients (50-64) when compared to other treatments.
Age not a barrier for successful HCT for AML
Subscribe to E-News
Receive new research summaries monthly.